SCHEMBL4340783

SCHEMBL4340783

COCCCN1Cc2cc(-c3cccnc3)cc(C)c2C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.47
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PARP1 P09874 2/20 0.46
PARP2 Q9UGN5 1/20 0.46
PIK3CG P48736 3/20 0.41
CYP11B1 P15538 3/20 0.39
CYP11B2 P19099 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP17A1 P05093 1/20 0.39
CYP19A1 P11511 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
KMT2A Q03164 1/20 0.38
ADAM17 P78536 1/20 0.37
MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4323296 0.94 ALDH1A1 (0.52) HTTALDH1A1SMN1; SMN2PARP1PIK3CG
SCHEMBL4329589 0.89 PIK3CG (0.45) HTTALDH1A1SMN1; SMN2PIK3CGCYP11B1
SCHEMBL4324337 0.85 PIK3CG (0.41) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL4342336 0.83 CYP11B2 (0.46) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL8231100 0.83 PIK3CG (0.46) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL4334126 0.81 PIK3CG (0.45) ALDH1A1SMN1; SMN2PIK3CGCYP11B1CYP11B2
SCHEMBL4324289 0.81 PIK3CG (0.47) PARP1PIK3CGCYP11B1CYP11B2CYP1A2
SCHEMBL2027087 0.80 DHPS (0.55) ALDH1A1SMN1; SMN2PARP1PIK3CGCYP11B1
SCHEMBL4331807 0.80 PIK3CG (0.58) PIK3CGCYP11B1CYP11B2CYP1A2CYP17A1
SCHEMBL2019134 0.80 PIK3CG (0.47) PIK3CGCYP11B1CYP11B2CYP1A2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US claimed
EP-1986998-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING SOINDOLONES AstraZeneca AB (SE) 2008-11-05 EP claimed
WO-2007095024-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ΓSOINDOLONES ASTRAZENECA AB (SE) 2007-08-23 WO claimed
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US disclosed
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US disclosed
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones ASTRAZENECA AB (SE) 2009-06-11 US disclosed
WO-2007095024-A1 METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ΓSOINDOLONES ASTRAZENECA AB (SE) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149505-A1 Metabotropic Glutamate Receptor-Potentiating Isoindolones GRM1, GRIN1, GRM3 HTT 1498/4885ALDH1A1 2048/4885SMN1; SMN2 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.